Previous studies indicate that R-cad expression usually diminishes with cancer progression in tumorigenic cell lines via methylation or down-regulation; such changes have been detected in mammary tumors [20], gastric carcinomas [21], nasopharyngeal carcinoma [25] and colorectal cancer [26]. This evidence concerns the gene CDH4 and breast cancer.